University Hospitals Harrington Heart & Vascular Institute Participates in Study of Redo–Transcatheter Aortic Valve Replacement with Self-Expanding Valves

Innovations in Cardiovascular Medicine & Surgery | September 2026

Redo transcatheter aortic valve replacement (TAVR) for failed transcatheter heart valves is expected to increase. However, data on outcomes with self-expanding valves remain limited. To add to the knowledge base, the study team, including senior author Guilherme Attizzani, MD, Director of the Valve and Structural Heart Disease Center at University Hospitals Harrington Heart & Vascular Institute, (pictured above) evaluated procedural, clinical and quality-of-life outcomes following redo-TAVR using self-expanding Evolut valves -- comparing these outcomes with those among a contemporary native TAVR cohort. Data came from the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry and were analyzed and compared with outcomes after native-valve TAVR using the same valve platform during the same study period. The primary endpoints were all-cause mortality, stroke and readmission at 30 days and one year. In a national registry, redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR. These findings support redo-TAVR with Evolut as a feasible and effective treatment strategy in appropriately selected patients.